These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 14609583)

  • 1. Diagnostic challenges of using CSF assay of tau and beta-amyloid(42) in atypical degenerative dementias of the Alzheimer type.
    Wagner M; Teichner G; Bachman DL
    Arch Clin Neuropsychol; 2003 Dec; 18(8):893-903. PubMed ID: 14609583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
    Koopman K; Le Bastard N; Martin JJ; Nagels G; De Deyn PP; Engelborghs S
    Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
    Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
    Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.
    Schoonenboom NS; van der Flier WM; Blankenstein MA; Bouwman FH; Van Kamp GJ; Barkhof F; Scheltens P
    Neurobiol Aging; 2008 May; 29(5):669-75. PubMed ID: 17208336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
    Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
    de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
    J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF biomarkers for mild cognitive impairment.
    Blennow K
    J Intern Med; 2004 Sep; 256(3):224-34. PubMed ID: 15324365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages.
    Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A
    Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biochemical markers for Alzheimer disease].
    Czarna JM; Waldemar G; Heegaard NH
    Ugeskr Laeger; 2006 Mar; 168(10):1010-4. PubMed ID: 16522291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
    Lewczuk P; Kornhuber J; Vanderstichele H; Vanmechelen E; Esselmann H; Bibl M; Wolf S; Otto M; Reulbach U; Kölsch H; Jessen F; Schröder J; Schönknecht P; Hampel H; Peters O; Weimer E; Perneczky R; Jahn H; Luckhaus C; Lamla U; Supprian T; Maler JM; Wiltfang J
    Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnosing the mild cognitive impairment stage of Alzheimer's disease].
    Maruyama M; Matsui T; Tanji H; Ootsuki M; Nemoto M; Tomita N; Okamura N; Matsushita S; Higuchi S; Kodama M; Arai H; Sasaki H
    Seishin Shinkeigaku Zasshi; 2004; 106(3):269-80. PubMed ID: 15164576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?
    Clark CM; Xie S; Chittams J; Ewbank D; Peskind E; Galasko D; Morris JC; McKeel DW; Farlow M; Weitlauf SL; Quinn J; Kaye J; Knopman D; Arai H; Doody RS; DeCarli C; Leight S; Lee VM; Trojanowski JQ
    Arch Neurol; 2003 Dec; 60(12):1696-702. PubMed ID: 14676043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
    Stefani A; Martorana A; Bernardini S; Panella M; Mercati F; Orlacchio A; Pierantozzi M
    J Neurol Sci; 2006 Dec; 251(1-2):124-8. PubMed ID: 17097109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.
    Galasko D
    J Neural Transm Suppl; 1998; 53():209-21. PubMed ID: 9700659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.
    Formichi P; Battisti C; Radi E; Federico A
    J Cell Physiol; 2006 Jul; 208(1):39-46. PubMed ID: 16447254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.
    Maddalena A; Papassotiropoulos A; Müller-Tillmanns B; Jung HH; Hegi T; Nitsch RM; Hock C
    Arch Neurol; 2003 Sep; 60(9):1202-6. PubMed ID: 12975284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration.
    Kapaki E; Paraskevas GP; Papageorgiou SG; Bonakis A; Kalfakis N; Zalonis I; Vassilopoulos D
    Alzheimer Dis Assoc Disord; 2008; 22(1):47-53. PubMed ID: 18317246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease.
    Grossman M; Farmer J; Leight S; Work M; Moore P; Van Deerlin V; Pratico D; Clark CM; Coslett HB; Chatterjee A; Gee J; Trojanowski JQ; Lee VM
    Ann Neurol; 2005 May; 57(5):721-9. PubMed ID: 15852395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.